Cytokine Release Syndrome Treatment Market Report 2026

Cytokine Release Syndrome Treatment Market Overview

• Cytokine Release Syndrome Treatment market size has reached to $1.42 billion in 2025 • Expected to grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.3% • Growth Driver: Increasing Prevalence Of Cancer Treatments Drives Growth In Cytokine Release Syndrome Treatment Market • Market Trend: Advancements In Drug Delivery Technologies Enhancing Cytokine Release Syndrome Treatment • North America was the largest region in 2025.

What Is Covered Under Cytokine Release Syndrome Treatment Market?

Cytokine release syndrome (CRS) treatment refers to medical interventions designed to manage and mitigate the severe inflammatory response triggered by cytokine release, associated with certain therapies such as CAR-T cell treatments. It helps control symptoms, reduce inflammation, and improve patient outcomes during intense cytokine reactions. The main drug types of cytokine release syndrome treatments include corticosteroids, monoclonal antibodies, and other immunosuppressants. Corticosteroids are a type of drug that helps reduce inflammation in the body and that works by mimicking the effects of hormones produced by the adrenal glands, which help control inflammation and the immune system. The administration types include intravenous, subcutaneous, and oral for applications including oncological treatments, autoimmune disorders, and others. The end user include are hospitals, specialty clinics, and home care settings.

What Is The Cytokine Release Syndrome Treatment Market Growth Forecast?

The cytokine release syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $2.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing use of next-generation immunotherapies, rising investments in cytokine modulation research, expansion of oncology treatment centers, growing focus on personalized immune management, development of novel anti-inflammatory biologics. Major trends in the forecast period include increasing use of il-6 and il-1 targeted therapies, rising adoption of monoclonal antibodies for crs management, expansion of hospital-based crs treatment protocols, growing integration of early diagnostic monitoring, improved supportive care management strategies.

Global Cytokine Release Syndrome Treatment Market Segmentation

1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants 2) By Administration: Intravenous, Subcutaneous, Oral 3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications 4) By End User: Hospitals, Specialty Clinics, Home Care Settings Subsegments: 1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone 2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist) 3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors

What Is The Driver Of The Cytokine Release Syndrome Treatment Market?

The increasing prevalence of cancer treatments is expected to propel the growth of the cytokine release syndrome (CRS) treatment market going forward. The growing prevalence of cancer treatments is driven by the rising global incidence of cancer and advancements in diagnostic technologies, which enable earlier detection and a broader range of treatment options. Additionally, improved survival rates and expanded access to healthcare contribute to the growing demand for these therapies. CRS treatment involves supportive care, anti-cytokine therapies, and ongoing monitoring to manage symptoms and mitigate the inflammatory response caused by cancer treatments. For instance, in May 2024, according to the National Health Service (NHS), a UK-based healthcare system, almost 340,000 people received their first treatment for cancer over the last year between April 2023 and March 2024. Further, levels of urgent suspected cancer referrals hit a new record in March 2024, with the 12,554 patients seen per working day a new record high, exceeding the previous record of 12,376 patients seen per working day in July 2023. Therefore, the increasing prevalence of cancer treatments is driving the cytokine release syndrome treatment industry.

Key Players In The Global Cytokine Release Syndrome Treatment Market

Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.

Global Cytokine Release Syndrome Treatment Market Trends and Insights

Major companies operating in the cytokine release syndrome treatment market are advancing drug delivery technologies such as intravenous infusion to improve treatment precision, reduce side effects, and enhance patient outcomes. Intravenous infusion in the treatment of cytokine release syndrome allows fast and accurate administration of drugs into the bloodstream, ensuring prompt therapeutic action. For instance, in September 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received regulatory approval for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody, from the Ministry of Health, Labor, and Welfare, a Japan-based government authority, to treat cytokine release syndrome (CRS) induced by various cancer therapies. Actemra Intravenous Infusion (available in 80 mg, 200 mg, and 400 mg doses) is an additional indication in treating cytokine release syndrome (CRS) caused by cancer therapy. With this new indication, Actemra can now be used as an anti-cytokine therapy for CRS resulting from cancer treatments beyond tumor-specific T-cell infusion therapy.

What Are Latest Mergers And Acquisitions In The Cytokine Release Syndrome Treatment Market?

In March 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Harpoon Therapeutics for $680 million. Merck is acquiring Harpoon Therapeutics to broaden its portfolio of cancer therapies, particularly focusing on T-cell engagers. This includes Harpoon's lead candidate, MK-6070 (formerly HPN328), which targets delta-like ligand 3 (DLL3), a protein associated with small cell lung cancer (SCLC) and neuroendocrine tumors. Harpoon Therapeutics is a US-based clinical-stage immunotherapy company specializing in TriTAC-XR, designed for cytokine release syndrome treatment.

Regional Insights

North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cytokine Release Syndrome Treatment Market?

The cytokine release syndrome treatment market consists of revenues earned by entities by providing services such as diagnostic services, clinical trials, hospital and medical services for treatment administration, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome treatment also includes sales of supportive medications such as analgesics and antipyretics, anti-cytokine therapies, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cytokine Release Syndrome Treatment Market Report 2026?

The cytokine release syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cytokine release syndrome treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.